Stichting European Myeloma Network

This phase 3 study tests whether adding daratumumab to a standard three-drug regimen (VRd) helps people with newly diagnosed multiple myeloma live longer without their cancer worsening. About 709 participants aged 18–70 who are eligible for high-dose therapy will receive either t…

This study tests a combination of four drugs (daratumumab, bortezomib, cyclophosphamide, and dexamethasone) in 41 people with multiple myeloma that has spread to other organs like skin, liver, or lungs. The goal is to see if this treatment can shrink or control the cancer. Partic…